Substance P receptors are differentially affected in Parkinson's and Alzheimer's disease
- 48 Downloads
We have quantified by receptor autoradiography the number of NK1 receptors, using [125I] Bolton-Hunter labeled substance P, in striatum and pallidum (internal (GPi) or external (GPe) segment) of patients suffering from Alzheimer's (AD) and Parkinson's disease (PD). When compared to non-neurologic controls, a significant increase in the number of NK1 sites has been observed in the striatum of PD patients. No significant differences were observed for the GPi and GPe. We observed no significant differences from controls in the number of NK1 sites in the striatum and pallidum of AD cases. However, the number of NK1 sites in the striatum of AD patients was significantly lower than that of PD patients. These results show that the expression of NK1 receptors in the basal ganglia is affected in PD.
Key wordsSubstance P NK1 receptors autoradiography Alzheimer's disease Parkinson's disease human basal ganglia
Unable to display preview. Download preview PDF.
- Buck SH, Burcher E (1986) A family of peptides with a brood of “receptors”. TPS 7: 65–68Google Scholar
- Burcher E (1988) The study of tachikinin receptors. Clin Exp Pharmacol Physiol 16: 539–543Google Scholar
- Dietl M, Probst A, Palacio JM (1986) Mapping of substance P receptor sites in the human brain: high densities in the substantia innominata and effect of senile dementia. Soc Neurosci Abstracts 12: 831Google Scholar
- Graybiel AM (1986) Neuropeptides in the basal ganglia. In: Martin JB, Barchas JD (eds) Neuropeptides in neurologic and psychiatric disease. Association for research in nervous and mental disease, vol 64. Raven Press, New York, pp 135–161Google Scholar
- Hornykiewick O, Kish SJ (1986) Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45: 19–34Google Scholar
- Joyce JN (1991a) Differential response of striatal dopamine receptor subtypes and cholinergic muscarinic receptors to the loss of dopamine. I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine system. Exp Neurol 113: 261–276CrossRefPubMedGoogle Scholar
- Joyce JN, Hensler JG, Tejani-Butt SM (1991) Neurochemical lesioning techniques for assessing regulation of monoamine receptors. In: Conn PM (ed) Methods in neurosciences, 7. Academic Press, San Diego, pp 216–240Google Scholar
- Murray AM, Weihmueller F, Marshall JF, Joyce JN (1991) Disturbances in pre- and postsynaptic dopamine systems in Parkinson's and Alzheimer's disease. Soc Neurosci Abstracts 21: 1260Google Scholar
- Roberts SJ, Hanaway J (1971) Atlas of the human brain in section. Lea and Febiger, Philadelphia, p 95Google Scholar
- Young WS III, Bonner TI, Brann MR (1976) Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc Natl Acad Sci USA 83: 9827–9831Google Scholar